These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 10760840)
1. The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers. Kanerva H; Kilkku O; Heinonen E; Helminen A; Rouru J; Tarpila S; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A Biopharm Drug Dispos; 1999 Oct; 20(7):327-34. PubMed ID: 10760840 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and safety of deramciclane during multiple oral dosing. Kanerva H; Kilkku O; Helminen A; Rouru J; Scheinin M; Huupponen R; Klebovich I; Drabant S; Urtti A Int J Clin Pharmacol Ther; 1999 Dec; 37(12):589-97. PubMed ID: 10599951 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of deramciclane and N-desmethylderamciclane after single and repeated oral doses in healthy volunteers. Huupponen R; Anttila M; Rouru J; Kanerva H; Miettinen T; Scheinin M Int J Clin Pharmacol Ther; 2004 Aug; 42(8):449-55. PubMed ID: 15366325 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of deramciclane in dogs after single oral and intravenous dosing and multiple oral dosing. Kanerva H; Huuskonen H; Alhonen-Raatesalmi A; Nevalainen T; Urtti A Biopharm Drug Dispos; 1998 Nov; 19(8):531-9. PubMed ID: 9840215 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of deramciclane in rabbits. Lengyel J; Bojti E; Bolehovszky A; Grézal G; Klebovich I; Magyar K Arzneimittelforschung; 1998 Nov; 48(11):1063-8. PubMed ID: 9850425 [TBL] [Abstract][Full Text] [Related]
6. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. Nemes KB; Abermann M; Bojti E; Grézal G; Al-Behaisi S; Klebovich I J Pharm Pharmacol; 2000 Jan; 52(1):47-51. PubMed ID: 10716602 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of deramciclane, a novel anxiolytic agent, after intravenous and oral administration. Huupponen R; Paija O; Salonen M; Björklund H; Rouru J; Anttila M Drugs R D; 2003; 4(6):339-45. PubMed ID: 14584962 [TBL] [Abstract][Full Text] [Related]
8. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Laine K; Ahokoski O; Huupponen R; Hänninen J; Palovaara S; Ruuskanen J; Björklund H; Anttila M; Rouru J Eur J Clin Pharmacol; 2003 Dec; 59(10):761-6. PubMed ID: 14566442 [TBL] [Abstract][Full Text] [Related]
9. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375 [TBL] [Abstract][Full Text] [Related]
10. Influence of food on the oral bioavailability of deramciclane from film-coated tablet in healthy male volunteers. Drabant S; Nemes KB; Horváth V; Tolokán A; Grézal G; Anttila M; Gachályi B; Kanerva H; Al-Behaisi S; Horvai G; Klebovich I Eur J Pharm Biopharm; 2004 Nov; 58(3):689-95. PubMed ID: 15451546 [TBL] [Abstract][Full Text] [Related]
12. Whole-body autoradiography and quantitative organ-level distribution study of deramciclane in rats. Hazai I; Pátfalusi M; Klebovich I; Urmös I J Pharm Pharmacol; 1999 Feb; 51(2):165-74. PubMed ID: 10217315 [TBL] [Abstract][Full Text] [Related]
13. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412 [TBL] [Abstract][Full Text] [Related]
14. Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits. Lengyel J; Bolehovszky A; Klebovich I; Aberman M; Magyar K Arzneimittelforschung; 1998 May; 48(5):455-60. PubMed ID: 9638311 [TBL] [Abstract][Full Text] [Related]
15. Studies of the side chain cleavage of deramciclane in rats with radiolabelled compounds. Magyar K; Lengyel J; Bolehovszky A; Grézal G; Klebovich I Eur J Pharm Sci; 2002 Mar; 15(2):217-23. PubMed ID: 11849919 [TBL] [Abstract][Full Text] [Related]
16. Application of overpressured layer chromatography combined with digital autoradiography and mass spectrometry in the study of deramciclane metabolism. Ludányi K; Vékey K; Szúnyog J; Mincsovics E; Karancsi T; Ujszászy K; Nemes KB; Klebovich I J AOAC Int; 1999; 82(2):231-8. PubMed ID: 10191528 [TBL] [Abstract][Full Text] [Related]
17. Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human. Monostory K; Kohalmy K; Ludányi K; Czira G; Holly S; Vereczkey L; Urmös I; Klebovich I; Kóbori L Drug Metab Dispos; 2005 Nov; 33(11):1708-16. PubMed ID: 16118331 [TBL] [Abstract][Full Text] [Related]
18. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022 [TBL] [Abstract][Full Text] [Related]
19. Different absorption profiles of deramciclane in man and in dog. Kanerva H; Klebovich I; Drabant S; Urtti A; Nevalainen T J Pharm Pharmacol; 1998 Oct; 50(10):1087-93. PubMed ID: 9821653 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]